OncLive® On Air

In today’s episode, we spoke with Triparna Sen, PhD, and Jacob Sands, MD. Dr Sen is a professor of internal medicine and the director of the Lung Cancer Preclinical Therapeutics Platform at the Ohio State University Comprehensive Cancer Center—James in Columbus. Dr Sands is associate chief of the Lowe Center for Thoracic Oncology and the oncology medical director of the International Patient Cente...

In today’s episode, we spoke with Erika P. Hamilton, MD, about the FDA approval of tucatinib (Tukysa) plus trastuzumab (Herceptin) and pertuzumab (Perjeta) for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy. Dr Hamilton is director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon R...

In this episode of Oncology Unplugged , host Chandler Park, MD, MSc, FACP, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Jame Abraham, MD, FACP, the enterprise chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and a professor of medicine at the Cleveland Clinic Lerner College of Medicine in Ohio. Their discussion centered on...

In this episode, produced in coordination with Oncology Nursing News ®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed how on-body subcutaneous administration methods could allow for select at-home administration of therapies for patients with multiple myeloma. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland...

In today’s episode, we spoke with Angeles Alvarez Secord, MD, MHSc. Dr Secord is a professor of obstetrics and gynecology and a member of Duke Cancer Institute in Durham, North Carolina. In our exclusive interview, Dr Secord discussed the emergence of B7-H4 as an attractive antibody-drug conjugate (ADC) target in gynecologic cancers, noting that expression rates of 80% to 90% or higher across endo...

From Discovery to Delivery: Charting Progress in Gynecologic Oncology , hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medi...

In this episode, produced in coordination with Oncology Nursing News ®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed how on-body subcutaneous administration methods are affecting multiple myeloma management and how these administrations could be a key focus of future health care initiatives. Dr Faiman is an adult nurse practitioner in the Department of Hem...

In today’s episode, we spoke with Vincent Chung, MD, about the development of atebimetinib (IMM-1-104) in metastatic pancreatic cancer. Dr Chung is a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California. In our exclusive interview, Dr Chung discussed MEK inhibition as a logical target in metastatic pancreatic cancer, the unique mechanism...

In today’s episode, we welcomed Ruben Mesa, MD, FACP, who outlined the significance of the August 2026 FDA approval of ropeginterferon alfa-2b-njft (Besremi) for the treatment of adult patients with essential thrombocythemia. Dr Mesa is senior vice president of Atrium Health and president and executive director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Charlotte, Nort...

In today’s episode, we spoke with Kim A. Reiss Binder, MD, about the August 2026 FDA approval of daraxonrasib (Rasonque) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multi-agent systemic therapy. Dr Reiss Binder is the assistant program director of the Hematology/Oncology Fellowship Progr...

In this episode, we spoke with Arndt Vogel, MD, a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre in Canada. In our exclusive interview, Dr Vogel highlighted the rationale and growing evidence for sequential FGFR inhibition in FGFR2 fusion–po...

In this episode, produced in coordination with Oncology Nursing News ®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed evolving administration strategies for multiple myeloma therapies, primarily focusing on subcutaneous and on-body administration. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a...

In today's episode, we spoke with Alissa Cooper, MD, and Noura Choudhury, MD. Dr Cooper is a physician at Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School in Boston, Massachusetts, and Dr Choudhury is an assistant professor of medicine at the University of Chicago in Illinois. In our exclusive interview, Drs Cooper and Choudhury discussed the evolving role of DLL3-...

In today's episode, we spoke with Jacqueline Aredo, MD, and Benjamin Bleiberg, MD. Dr Aredo is a thoracic oncologist at Mass General Brigham Cancer Institute in Boston, Massachusetts, and Dr Bleiberg is an adjunct assistant professor of medicine at the University of Pennsylvania Perelman School of Medicine in Philadelphia. In our exclusive interview, Drs Aredo and Bleiberg reflected on the experie...

Highlights from the PER® CME activity "OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Vinay K. Puduvalli, MD; Ruham Nasany, MD; and Angela Waanders, MD, MPH, MS; discuss advances in mole...

In today’s episode, we welcomed Tracy I. George, MD, who provided a pathologist’s perspective on the diagnosis and evolving management considerations for systemic mastocytosis. Dr George is president of the Innovation Business Unit and chief scientific officer at ARUP Laboratories and a professor of pathology at the Spencer Fox Eccles School of Medicine at the University of Utah in Salt Lake City....

In today’s episode, we spoke with Elias Jabbour, MD, and Dennis Kim, MD. Dr Jabbour is a professor of Leukemia at The University of Texas MD Anderson Cancer Center in Houston. Dr Kim is an associate professor at the Institute of Medical Science at the University of Toronto in Canada. In our exclusive interview, Drs Jabbour and Kim discussed the third-generation TKI olverembatinib (HQP1351), how it...

Highlights from the PER® CME activity "Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice " — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Joyce O’Shaughnessy, MD, Sarat Chandarlapaty, MD, PhD, Mi...

In today’s episode, we spoke with Philip A. Philip, MD. Dr Philip is the director of Gastrointestinal Oncology, co-director of the Pancreatic Cancer Center, and medical director of Research and Clinical Care Integration at the Henry Ford Cancer Institute in Detroit, Michigan. In our exclusive interview, Dr Philip discussed the February 2026 FDA approval of Optune Pax for lo cally advanced pancreat...

In this episode of Oncology Unplugged , host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Pashtoon Kasi, MD, MS, the medical director of GI Medical Oncology, the Rad Family Chair in Gastrointestinal Oncology, and an associate clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Orange Count...

In today’s episode, we spoke with Nataliya Uboha, MD, PhD. Dr Uboha is an associate professor and researcher in the Department of Medicine at the University of Wisconsin School of Medicine in Madison. In our exclusive interview, Dr Uboha discussed the August 2026 FDA approval of zanidatamab (Ziihera)-based regimens for first-line HER2-positive locally advanced or metastatic gastric cancer , and un...

In today’s episode, Narjust Florez, MD, and Jonathan Wesley Riess, MD, MS, hosted a discussion about the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer (NSCLC). Dr Florez is the associate medical director of the Cancer Care Access Program and a physician at Dana-Farber Cancer Institute, as well as an assistant professor of medicine and a faculty member at...

In today’s episode, we spoke with Davide Melisi, MD, PhD. Dr Melisi is an associate professor of medical oncology at the University of Verona in Italy. In our exclusive interview, Dr Melisi discussed the investigational oral KRAS G12D inhibitor INCB161734, its mechanism of action, what early data have shown with the agent, and the aims of the ongoing phase 3 DAWN-303 trial (NCT07522073) evaluating...

In today’s episode, we spoke with Raji Shameem, MD, and Shubham Pant, MD, MBBS. Dr Shameem is a clinical assistant professor of medicine at the Orlando College of Osteopathic Medicine, an assistant professor of Medicine at the University of Central Florida, and a physician at Orlando Health. Dr Pant is a professor in the Department of Gastrointestinal Medical Oncology and the Department of Investi...

Highlights from the PER® CME activity "SimulatED: Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma — Testing, Treatment, and Supportive Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below. In this podcast, experts Geoffrey Y. Ku, MD, and Sunnie Kim, MD, discuss essential biomarker testing fo...